CHRS - Coherus BioSciences, Inc.
14.84 0.00 (0.00%)
After hours: 5:22PM EDT
| Previous Close | 14.90 |
| Open | 14.93 |
| Bid | 14.85 x 800 |
| Ask | 15.85 x 900 |
| Day's Range | 14.48 - 15.11 |
| 52 Week Range | 8.32 - 20.66 |
| Volume | 330,883 |
| Avg. Volume | 772,216 |
| Market Cap | 1.028B |
| Beta (3Y Monthly) | 3.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.22 |
| Earnings Date | May 8, 2019 - May 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.00 |
- GlobeNewswire•9 hours ago
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., March 19, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective March 13, 2019, the compensation committee of the company’s.
- Markit•10 hours ago
See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
Coherus BioSciences Inc NASDAQ NMS:CHRSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining Bearish sentimentShort interest | PositiveShort interest is moderate for CHRS with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on March 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CHRS are favorable, with net inflows of $1.69 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- GlobeNewswire•yesterday
Coherus BioSciences Appoints Thomas Fitzpatrick Chief Legal Officer
Coherus BioSciences, Inc. (CHRS), today announced the addition of Thomas Fitzpatrick as its Chief Legal Officer. Mr. Fitzpatrick brings more than 20 years of executive-level legal experience to his role as leader of Coherus’ legal and compliance departments, reporting directly to Coherus President and CEO, Denny Lanfear. “Tom brings a passion for our mission, strong leadership skills and deep litigation insights to this critical position,” said Denny Lanfear, President and CEO of Coherus.
- Thomson Reuters StreetEvents•14 days ago
Edited Transcript of CHRS earnings conference call or presentation 28-Feb-19 9:30pm GMT
Q4 2018 Coherus BioSciences Inc Earnings Call
- GlobeNewswire•14 days ago
New Research: Key Drivers of Growth for American Tower Corporation (REIT), Lowe's Companies, Mimecast, Live Nation Entertainment, Intercept Pharmaceuticals, and Coherus BioSciences — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Motley Fool•19 days agoCoherus BioSciences Inc (CHRS) Q4 2018 Earnings Conference Call Transcript
CHRS earnings call for the period ending December 31, 2018.
- GlobeNewswire•19 days ago
Coherus BioSciences Reports Fourth Quarter and Full Year 2018 Financial Results
REDWOOD CITY, Calif., Feb. 28, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter and full year.
- GlobeNewswire•21 days ago
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March
REDWOOD CITY, Calif., Feb. 26, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare.
- GlobeNewswire•last month
Coherus BioSciences to Report Fourth Quarter and Full Year 2018 Financial Results on February 28th
REDWOOD CITY, Calif., Feb. 14, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that its fourth quarter and full year 2018 financial results will be released.
- Motley Fool•last month
Here's Why Coherus BioSciences Rose 48.7% in January
The company secured a deal paving the way to commercialize a generic version of the former best-selling drug in the world.
- GlobeNewswire•2 months ago
Coherus BioSciences Announces Filing of Patent Infringement Suit Against Amgen Directed to Amgen’s Humira Biosimilar Formulation
Each of the asserted Coherus patents is directed to stable formulations of adalimumab. “Coherus recognized early on the central role intellectual property would play in advancing biosimilars to market,” said Denny Lanfear, Chairman, CEO and President of Coherus.
- GlobeNewswire•2 months ago
Coherus BioSciences Announces Global Settlement with AbbVie Securing Rights to Commercialize its Adalimumab Biosimilar Candidate, CHS-1420
“Biosimilars have an essential role in our healthcare system to restrain cost increases while expanding access for patients,” said Denny Lanfear, Chairman, CEO and President of Coherus. CHS-1420 is among a number of significant biosimilar candidates in Coherus’ pipeline of high-value treatments for patients in need, which include the company’s biosimilar candidates directed to Enbrel®, Lucentis® and Eylea®. The company is currently preparing its biologics license application for CHS-1420 for submission to the U.S. Food and Drug Administration, with anticipated filing in late 2019.
- Simply Wall St.•2 months ago
Coherus BioSciences, Inc. (NASDAQ:CHRS) Is Expected To Breakeven
Coherus BioSciences, Inc.'s (NASDAQ:CHRS): Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The US$590m market-cap posted a loss in its most recent financial year of Read More...
- GlobeNewswire•2 months ago
Coherus BioSciences Secures $75 Million Credit Financing with HealthCare Royalty Partners
Coherus BioSciences, Inc. (CHRS), a commercial biosimilar company, today announced that it has entered into a $75 million senior secured credit facility agreement with Healthcare Royalty Partners. “We are pleased to have the renewed support of HealthCare Royalty Partners,” said Denny Lanfear, President and CEO of Coherus. “This investment reflects our continued confidence in the Coherus leadership team, as well as their ability to execute on their commercial plan,” said Clarke Futch, Managing Partner and Chairman of the Investment Committee of Healthcare Royalty Partners.
- GlobeNewswire•2 months ago
Coherus BioSciences Management to Present at The 37th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 02, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the 37th annual J.P. Morgan healthcare.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of CHRS earnings conference call or presentation 8-Nov-18 9:30pm GMT
Q3 2018 Coherus BioSciences Inc Earnings Call
